论文部分内容阅读
据2015年4月25日《中国科学报》援引报道,中科院上海药物所研究人员首次测定了该受体蛋白的高分辨率三维结构,并揭示了P2Y1R抑制剂分子的作用机理,为研究治疗血栓性疾病新药提供了重要依据,同时将开启G蛋白偶联受体(GPCR)药物研发的新方向。相关成果在线发表于《自然》杂志。靶向P2Y1R的药物目前仍处于研发阶段。大量研究表明,P2Y1R是极具潜力的新型药物靶点,但P2Y1R结构信息
According to a report in the China Science Bulletin on April 25, 2015, researchers at Shanghai Institute of Materia Medica, the Chinese Academy of Sciences, for the first time measured the high-resolution three-dimensional structure of the receptor protein and revealed the mechanism of action of the P2Y1R inhibitor molecule in order to study the treatment of thrombus The new drug for sexually transmitted diseases provides an important basis and will open new directions for the development of G protein coupled receptor (GPCR) drugs. Relevant results published online in the “Nature” magazine. Drugs targeting P2Y1R are still in the research and development phase. A large number of studies have shown that P2Y1R is a potential new drug target, but P2Y1R structure information